Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:

Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

CME information and select publications